Compare Gilead Sciences, Inc. (GILD) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs JD.Com Inc — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while JD.Com Inc trades at $26.9 (market cap $36.62B). The key difference: Gilead Sciences, Inc. is far larger — about 5× JD.Com Inc's market cap, and JD.Com Inc pays the higher dividend (3.72%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and JD.Com Inc for 85 Days on average.
| GILD | JD | |
|---|---|---|
Market Cap | $182.40B | $36.62B |
Volume | 4,469,821 | 6,571,477 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $34.53 |
52-Week Low | $116.74 | $25.19 |
Typical Hold Time | 111 Days | 85 Days |
Enterprise Value | $205.46B | $19.26B |
Dividend Yield | 2.23% | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
JD.com stock trades at $27.03, up 2.0% today, with a bullish technical signal and strong analyst consensus. The company reported revenue of $1.31 trillion in 2025, though net income declined to $19.63 billion. Recent news highlights potential EU approval for its $2.5 billion Ceconomy acquisition, a key strategic move.
The outlook is positive given deep valuation discounts (P/E 17.9, P/S 0.2) and robust cash flow, but risks include revenue pressure and regulatory scrutiny. Analyst price targets average $35.86, implying significant upside from current levels if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
